Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma

Federica Perrone, Simona Suardi, Elisa Pastore, Paola Casieri, Marta Orsenigo, Stefano Caramuta, Gianpaolo Dagrada, Marco Losa, Lisa Licitra, Paolo Bossi, Samantha Staurengo, Maria Oggionni, Laura Locati, Giulio Cantu, Massimo Squadrelli, Antonino Carbone, Marco A. Pierotti, Silvana Pilotti

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Purpose: The aim of this study was to acquire further insights into the pathogenetic pathways of head and neck squamous cell carcinomas (HNSCC) that may be useful for identifying new biomarkers instrumental in developing more specific treatment approaches. Experimental Design: Cell cycle regulators and epidermal growth factor receptor (EGFR) and BRAF genes were analyzed in a series of 90 oropharyngeal SCCs of a cohort of surgically treated patients from a single institution, and the results were matched with the presence of high-risk human papillomavirus (HR-HPV) DNA and the TP53 status. Results: At least four distinct groups of tumors were identified sharing a common histology but displaying different molecular/cytogenetic patterns: (a) 19% were HPV-positive SCCs whose lack of alterations of the investigated genes could explain their particular natural history, which requires less aggressive treatment; (b) 37% were HPV-negative SCCs carrying TP53 mutations, which may be more effectively treated by drugs acting through p53-independent apoptosis; (c) 34% were HPV-negative SCCs carrying wild-type TP53 and loss of 9p21 (p16INK4a and p15INK4b) and/or cyclin D1 overexpression that justify treatment with DNA-damaging drugs followed by cell cycle inhibitors; and (d) 10% were HPV-negative lacking tumor suppressor genes and cell cycle alterations. The second, third, and fourth groups also showed an increased copy number of EGFR and chromosome 7 (43%) that might justify the additional or alternative use of EGFR inhibitors. Conclusions: Our findings suggest that assessing HPV, TP53, 9p21, and EGFR status may be crucial to finding more tailored and beneficial treatments for oropharyngeal SCCs.

Original languageEnglish
Pages (from-to)6643-6651
Number of pages9
JournalClinical Cancer Research
Volume12
Issue number22
DOIs
Publication statusPublished - Nov 15 2006

Fingerprint

Cytogenetics
Squamous Cell Carcinoma
Epidermal Growth Factor Receptor
Cell Cycle
erbB-1 Genes
Chromosomes, Human, Pair 7
DNA
Cyclin D1
Therapeutics
Tumor Suppressor Genes
Natural History
Pharmaceutical Preparations
Histology
Research Design
Biomarkers
Apoptosis
Mutation
Genes
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Perrone, F., Suardi, S., Pastore, E., Casieri, P., Orsenigo, M., Caramuta, S., ... Pilotti, S. (2006). Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clinical Cancer Research, 12(22), 6643-6651. https://doi.org/10.1158/1078-0432.CCR-06-1759

Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. / Perrone, Federica; Suardi, Simona; Pastore, Elisa; Casieri, Paola; Orsenigo, Marta; Caramuta, Stefano; Dagrada, Gianpaolo; Losa, Marco; Licitra, Lisa; Bossi, Paolo; Staurengo, Samantha; Oggionni, Maria; Locati, Laura; Cantu, Giulio; Squadrelli, Massimo; Carbone, Antonino; Pierotti, Marco A.; Pilotti, Silvana.

In: Clinical Cancer Research, Vol. 12, No. 22, 15.11.2006, p. 6643-6651.

Research output: Contribution to journalArticle

Perrone, F, Suardi, S, Pastore, E, Casieri, P, Orsenigo, M, Caramuta, S, Dagrada, G, Losa, M, Licitra, L, Bossi, P, Staurengo, S, Oggionni, M, Locati, L, Cantu, G, Squadrelli, M, Carbone, A, Pierotti, MA & Pilotti, S 2006, 'Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma', Clinical Cancer Research, vol. 12, no. 22, pp. 6643-6651. https://doi.org/10.1158/1078-0432.CCR-06-1759
Perrone, Federica ; Suardi, Simona ; Pastore, Elisa ; Casieri, Paola ; Orsenigo, Marta ; Caramuta, Stefano ; Dagrada, Gianpaolo ; Losa, Marco ; Licitra, Lisa ; Bossi, Paolo ; Staurengo, Samantha ; Oggionni, Maria ; Locati, Laura ; Cantu, Giulio ; Squadrelli, Massimo ; Carbone, Antonino ; Pierotti, Marco A. ; Pilotti, Silvana. / Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 22. pp. 6643-6651.
@article{e7051ee627cd47109e111f3a22edf689,
title = "Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma",
abstract = "Purpose: The aim of this study was to acquire further insights into the pathogenetic pathways of head and neck squamous cell carcinomas (HNSCC) that may be useful for identifying new biomarkers instrumental in developing more specific treatment approaches. Experimental Design: Cell cycle regulators and epidermal growth factor receptor (EGFR) and BRAF genes were analyzed in a series of 90 oropharyngeal SCCs of a cohort of surgically treated patients from a single institution, and the results were matched with the presence of high-risk human papillomavirus (HR-HPV) DNA and the TP53 status. Results: At least four distinct groups of tumors were identified sharing a common histology but displaying different molecular/cytogenetic patterns: (a) 19{\%} were HPV-positive SCCs whose lack of alterations of the investigated genes could explain their particular natural history, which requires less aggressive treatment; (b) 37{\%} were HPV-negative SCCs carrying TP53 mutations, which may be more effectively treated by drugs acting through p53-independent apoptosis; (c) 34{\%} were HPV-negative SCCs carrying wild-type TP53 and loss of 9p21 (p16INK4a and p15INK4b) and/or cyclin D1 overexpression that justify treatment with DNA-damaging drugs followed by cell cycle inhibitors; and (d) 10{\%} were HPV-negative lacking tumor suppressor genes and cell cycle alterations. The second, third, and fourth groups also showed an increased copy number of EGFR and chromosome 7 (43{\%}) that might justify the additional or alternative use of EGFR inhibitors. Conclusions: Our findings suggest that assessing HPV, TP53, 9p21, and EGFR status may be crucial to finding more tailored and beneficial treatments for oropharyngeal SCCs.",
author = "Federica Perrone and Simona Suardi and Elisa Pastore and Paola Casieri and Marta Orsenigo and Stefano Caramuta and Gianpaolo Dagrada and Marco Losa and Lisa Licitra and Paolo Bossi and Samantha Staurengo and Maria Oggionni and Laura Locati and Giulio Cantu and Massimo Squadrelli and Antonino Carbone and Pierotti, {Marco A.} and Silvana Pilotti",
year = "2006",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-06-1759",
language = "English",
volume = "12",
pages = "6643--6651",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma

AU - Perrone, Federica

AU - Suardi, Simona

AU - Pastore, Elisa

AU - Casieri, Paola

AU - Orsenigo, Marta

AU - Caramuta, Stefano

AU - Dagrada, Gianpaolo

AU - Losa, Marco

AU - Licitra, Lisa

AU - Bossi, Paolo

AU - Staurengo, Samantha

AU - Oggionni, Maria

AU - Locati, Laura

AU - Cantu, Giulio

AU - Squadrelli, Massimo

AU - Carbone, Antonino

AU - Pierotti, Marco A.

AU - Pilotti, Silvana

PY - 2006/11/15

Y1 - 2006/11/15

N2 - Purpose: The aim of this study was to acquire further insights into the pathogenetic pathways of head and neck squamous cell carcinomas (HNSCC) that may be useful for identifying new biomarkers instrumental in developing more specific treatment approaches. Experimental Design: Cell cycle regulators and epidermal growth factor receptor (EGFR) and BRAF genes were analyzed in a series of 90 oropharyngeal SCCs of a cohort of surgically treated patients from a single institution, and the results were matched with the presence of high-risk human papillomavirus (HR-HPV) DNA and the TP53 status. Results: At least four distinct groups of tumors were identified sharing a common histology but displaying different molecular/cytogenetic patterns: (a) 19% were HPV-positive SCCs whose lack of alterations of the investigated genes could explain their particular natural history, which requires less aggressive treatment; (b) 37% were HPV-negative SCCs carrying TP53 mutations, which may be more effectively treated by drugs acting through p53-independent apoptosis; (c) 34% were HPV-negative SCCs carrying wild-type TP53 and loss of 9p21 (p16INK4a and p15INK4b) and/or cyclin D1 overexpression that justify treatment with DNA-damaging drugs followed by cell cycle inhibitors; and (d) 10% were HPV-negative lacking tumor suppressor genes and cell cycle alterations. The second, third, and fourth groups also showed an increased copy number of EGFR and chromosome 7 (43%) that might justify the additional or alternative use of EGFR inhibitors. Conclusions: Our findings suggest that assessing HPV, TP53, 9p21, and EGFR status may be crucial to finding more tailored and beneficial treatments for oropharyngeal SCCs.

AB - Purpose: The aim of this study was to acquire further insights into the pathogenetic pathways of head and neck squamous cell carcinomas (HNSCC) that may be useful for identifying new biomarkers instrumental in developing more specific treatment approaches. Experimental Design: Cell cycle regulators and epidermal growth factor receptor (EGFR) and BRAF genes were analyzed in a series of 90 oropharyngeal SCCs of a cohort of surgically treated patients from a single institution, and the results were matched with the presence of high-risk human papillomavirus (HR-HPV) DNA and the TP53 status. Results: At least four distinct groups of tumors were identified sharing a common histology but displaying different molecular/cytogenetic patterns: (a) 19% were HPV-positive SCCs whose lack of alterations of the investigated genes could explain their particular natural history, which requires less aggressive treatment; (b) 37% were HPV-negative SCCs carrying TP53 mutations, which may be more effectively treated by drugs acting through p53-independent apoptosis; (c) 34% were HPV-negative SCCs carrying wild-type TP53 and loss of 9p21 (p16INK4a and p15INK4b) and/or cyclin D1 overexpression that justify treatment with DNA-damaging drugs followed by cell cycle inhibitors; and (d) 10% were HPV-negative lacking tumor suppressor genes and cell cycle alterations. The second, third, and fourth groups also showed an increased copy number of EGFR and chromosome 7 (43%) that might justify the additional or alternative use of EGFR inhibitors. Conclusions: Our findings suggest that assessing HPV, TP53, 9p21, and EGFR status may be crucial to finding more tailored and beneficial treatments for oropharyngeal SCCs.

UR - http://www.scopus.com/inward/record.url?scp=33845297649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845297649&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-1759

DO - 10.1158/1078-0432.CCR-06-1759

M3 - Article

VL - 12

SP - 6643

EP - 6651

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -